Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [Erratum]
Ashkenazi M, Sity S, Sarouk I, et al. J Asthma Allergy. 2018;11:101–107. On page 101, in the Conclusion section, the text “omlaizumb” should have been “omalizumab”. Read the original article.
Main Authors: | Ashkenazi M, Sity S, Sarouk I, Bar Aluma BE, Dagan A, Bezalel Y, Bentur L, De Boeck K, Efrati O |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Journal of Asthma and Allergy |
Online Access: | https://www.dovepress.com/erratumomalizumab-in-allergic-bronchopulmonary-aspergillosis-in-p-peer-reviewed-article-JAA |
Similar Items
-
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
by: Ashkenazi M, et al.
Published: (2018-06-01) -
Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
by: Sylvia Lehmann, et al.
Published: (2014-10-01) -
Allergic bronchopulmonary aspergillosis treated successfully with omalizumab
by: R. Aguiar, et al.
Published: (2017-09-01) -
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
by: Ibrahim Ahmed Janahi, et al.
Published: (2017-01-01) -
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis
by: Soheila Alyasin, et al.
Published: (2018-01-01)